Author/Authors :
Qu، Junwei نويسنده Department of Gynecological Oncology Surgery, Jiangsu Cancer Hospital and Institute, Nanjing 210009, China , , Che، Yena نويسنده Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China , , Xu، Pei نويسنده Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China , , Xia، Yanjie نويسنده Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China , , Wu، Xiaoke نويسنده Department of Obstetrics and Gynecology, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China , , Wang، Yong نويسنده Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China ,
Abstract :
Background: This research investigated the response of vascular active factors, vascular
endothelial growth factor (VEGF) and angiotensin-II (AT-II) to ovarian stimulation during
24 hours in patients with polycystic ovary syndrome (PCOS).
Materials and Methods: In this clinical trial study, 52 patients with PCOS and 8 control
cases were stimulated with human chorionic gonadotropin (HCG) on the 4th to 7th day
of the patients’ natural or induced menstrual cycles. We measured VEGF and AT-II by
radioimmunoassay before the injection (0 hour) and 3, 8, 12, 18 and 24 hours after the
stimulation.
Results: After ovarian stimulation, there was substantially higher level of VEGF in
typical PCOS patients than the other three groups at the 3 hour time point (p < 0.05),
while there were no significant differences in VEGF at all the other time points
among the four groups. As for AT-II, before and at all time points after the ovarian
stimulation, it seemed that the AT-II levels in patients’ sera with different phenotypes
of PCOS by the Rotterdam criteria were all higher than in the control group
although the differences were not statistically significant. The level of AT-II in typical
PCOS patients was also significantly higher than the other three groups at the 3
hour time point (p < 0.05), while no significant differences at all the other time points
among the four groups were observed.
Conclusion: The response to the stimulation varied among patients with different phenotypes
of PCOS according to the Rotterdam criteria. Serum VEGF and AT-II were possible
contributors to an increased risk of developing ovarian hyperstimulation syndrome
(OHSS) in patients with typical PCOS during the early follicular phase (3 hours) after
ovarian stimulation (Registration Number: NCT02265861).